Ozier Daniel, Zivkovic Nevena, Elbaz-Greener Gabby, Singh Sheldon M, Wijeysundera Harindra C
University of Toronto, Toronto, Ontario, Canada.
University of Toronto, Toronto, Ontario, Canada; Division of Cardiology and Cardiac Surgery, Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Can J Cardiol. 2017 Dec;33(12):1660-1667. doi: 10.1016/j.cjca.2017.08.012. Epub 2017 Sep 1.
Transcatheter aortic valve implantation (TAVI) is the preferred alternative to traditional surgical aortic valve replacement; however, it remains expensive. One potential driver of cost is the need for postprocedural monitoring for conduction abnormalities after TAVI. Given the paucity of literature on the optimal length of monitoring, we aimed to determine when clinically significant conduction abnormalities leading to permanent pacemaker (PPM) insertion after TAVI were first identified.
We identified all patients in the Sunnybrook Health Sciences Centre TAVI registry (Toronto, Canada) who underwent TAVI between 2009 and 2016, excluding those with pre-existing PPMs or those who underwent emergency open heart surgery. Through dedicated chart review, the timing and type of conduction abnormalities leading to PPM were recorded. Patients were divided according to the timing of conduction abnormality: during the procedure vs after the procedure.
The overall PPM insertion rate was 15.6% (80 of 512 cases), with all but 1 patient receiving a PPM for class I indications. PPMs were inserted for complete heart block/high-grade atrioventricular block (91.3%), severe sinus node dysfunction (3.8%), and alternating bundle branch block (3.8%). Of these conduction abnormalities, 55.0% occurred during the procedure (intraprocedure; n = 44 patients). The mean time to the development of a conduction abnormality necessitating PPM was 1.2 days (interquartile range, 0-2 days), with 88.8% occurring within 72 hours of the procedure (n = 71 patients). In the entire TAVI cohort, < 3% had conduction abnormalities beyond 48 hours after the procedure leading to PPM.
The majority of conduction abnormalities leading to PPM insertion after TAVI occur in the very early periprocedural period, suggesting that early mobilization and discharge will be safe from a conduction standpoint.
经导管主动脉瓣植入术(TAVI)是传统外科主动脉瓣置换术的首选替代方案;然而,其费用仍然高昂。成本的一个潜在驱动因素是TAVI术后需要对传导异常进行监测。鉴于关于最佳监测时长的文献匮乏,我们旨在确定TAVI术后首次发现导致永久起搏器(PPM)植入的具有临床意义的传导异常的时间。
我们在桑尼布鲁克健康科学中心TAVI注册研究(加拿大多伦多)中确定了2009年至2016年间接受TAVI的所有患者,排除那些已植入PPM或接受急诊心脏直视手术的患者。通过专门的病历审查,记录导致PPM的传导异常的时间和类型。患者根据传导异常的时间进行分组:术中与术后。
总体PPM植入率为15.6%(512例中的80例),除1例患者外,所有患者接受PPM均为I类适应证。植入PPM的原因包括完全性心脏传导阻滞/高度房室传导阻滞(91.3%)、严重窦房结功能障碍(3.8%)和交替性束支传导阻滞(3.8%)。在这些传导异常中,55.0%发生在术中(术中;n = 44例患者)。导致需要植入PPM的传导异常发生的平均时间为1.2天(四分位间距,0 - 2天),88.8%发生在术后72小时内(n = 71例患者)。在整个TAVI队列中,< 3%的患者在术后48小时后出现导致PPM的传导异常。
TAVI术后导致PPM植入的大多数传导异常发生在围手术期的极早期,这表明从传导角度来看,早期活动和出院是安全的。